299 related articles for article (PubMed ID: 33576497)
41. Dupilumab-associated ocular manifestations: A review of clinical presentations and management.
Wu D; Daniel BS; Lai AJX; Wong N; Lim DKA; Murrell DF; Lim BXH; Mehta JS; Lim CHL
Surv Ophthalmol; 2022; 67(5):1419-1442. PubMed ID: 35181280
[TBL] [Abstract][Full Text] [Related]
42. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
43. Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis.
Cheng J; Jiang L; Morrow NC; Avdic A; Fairley JA; Ling JJ; Greiner MA
J Am Acad Dermatol; 2021 Jul; 85(1):265-267. PubMed ID: 32956738
[No Abstract] [Full Text] [Related]
44. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
Faiz S; Giovannelli J; Podevin C; Jachiet M; Bouaziz JD; Reguiai Z; Nosbaum A; Lasek A; Ferrier le Bouedec MC; Du Thanh A; Raison-Peyron N; Tetart F; Duval-Modeste AB; Misery L; Aubin F; Dompmartin A; Morice C; Droitcourt C; Soria A; Arnault JP; Delaunay J; Mahé E; Richard MA; Schoeffler A; Lacour JP; Begon E; Walter-Lepage A; Dillies AS; Rappelle-Duruy S; Barete S; Bellon N; Bénéton N; Valois A; Barbarot S; Sénéchal J; Staumont-Sallé D;
J Am Acad Dermatol; 2019 Jul; 81(1):143-151. PubMed ID: 30825533
[TBL] [Abstract][Full Text] [Related]
45. Safety and Efficacy of Dupilumab in an Atopic Adolescent With Primary Immune Deficiency.
Tanner JF; Knutsen AP; Siegfried E
Dermatitis; 2021 Oct; 32(1S):e91-e92. PubMed ID: 34677168
[No Abstract] [Full Text] [Related]
46. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
47. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.
Magdaleno-Tapial J; Valenzuela-Oñate C; García-Legaz-Martínez M; Martínez-Domenech Á; Pérez-Ferriols A
Australas J Dermatol; 2020 May; 61(2):e223-e225. PubMed ID: 31766073
[TBL] [Abstract][Full Text] [Related]
48. Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study.
Schneeweiss MC; Wyss R; Chin K; Merola JF; Silverberg JI; Mostaghimi A; Schneeweiss S
Dermatitis; 2022 Nov-Dec 01; 33(6S):S73-S82. PubMed ID: 35170520
[TBL] [Abstract][Full Text] [Related]
49. Transient Increase in Circulating Basophils and Eosinophils in Dupilumab-associated Conjunctivitis in Patients with Atopic Dermatitis.
Katsuta M; Ishiuji Y; Matsuzaki H; Yasuda KI; Kharma B; Nobeyama Y; Hayashi T; Tokura Y; Asahina A
Acta Derm Venereol; 2021 Jun; 101(6):adv00483. PubMed ID: 34043018
[No Abstract] [Full Text] [Related]
50. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration.
Wang Y; Jorizzo JL
J Am Acad Dermatol; 2021 Apr; 84(4):1010-1014. PubMed ID: 33725800
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience.
Ribero S; Giura MT; Viola R; Ramondetta A; Siliquini N; Cardone P; Tonella L; Quaglino P; Dapavo P; Panzone M; Ortoncelli M; Fierro MT
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e380-e383. PubMed ID: 31960496
[No Abstract] [Full Text] [Related]
52. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre.
Olesen CM; Holm JG; Nørreslet LB; Serup JV; Thomsen SF; Agner T
J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1562-1568. PubMed ID: 30959559
[TBL] [Abstract][Full Text] [Related]
53. Punctal stenosis associated with dupilumab therapy for atopic dermatitis.
Lee DH; Cohen LM; Yoon MK; Tao JP
J Dermatolog Treat; 2021 Nov; 32(7):737-740. PubMed ID: 31888394
[TBL] [Abstract][Full Text] [Related]
54. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients.
Ludriksone L; Elsner P; Schliemann S
J Dtsch Dermatol Ges; 2019 Dec; 17(12):1278-1280. PubMed ID: 31829527
[No Abstract] [Full Text] [Related]
55. The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis.
Tosuji E; Inaba Y; Muraoka K; Kunimoto K; Kaminaka C; Yamamoto Y; Jinnin M
Drug Discov Ther; 2022 Sep; 16(4):164-168. PubMed ID: 35989284
[TBL] [Abstract][Full Text] [Related]
56. Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
Loret L; Ninclaus V; Dendooven A; Lapeere H; Kreps EO
Eur J Dermatol; 2021 Dec; 31(6):843-844. PubMed ID: 34933837
[No Abstract] [Full Text] [Related]
57. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.
Ivert LU; Wahlgren CF; Ivert L; Lundqvist M; Bradley M
Acta Derm Venereol; 2019 Apr; 99(4):375-378. PubMed ID: 30653240
[TBL] [Abstract][Full Text] [Related]
58. Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis.
Casale F; Nguyen C; Dobry A; Smith J; Mesinkovska NA
Australas J Dermatol; 2022 Aug; 63(3):394-397. PubMed ID: 35460570
[No Abstract] [Full Text] [Related]
59. Median canaliform nail dystrophy of Heller in a patient with atopic dermatitis: 'miraculous' healing with dupilumab.
Giura MT; Viola R; Dika E; Ribero S; Ortoncelli M
Clin Exp Dermatol; 2020 Jul; 45(5):601-602. PubMed ID: 31889326
[No Abstract] [Full Text] [Related]
60. Ocular surface disease associated with dupilumab treatment for atopic diseases.
Utine CA; Li G; Asbell P; Pflugfelder S; Akpek E
Ocul Surf; 2021 Jan; 19():151-156. PubMed ID: 32439390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
